{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:09:48Z","timestamp":1793196588271,"version":"4.5.0"},"reference-count":142,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Gastroenterol Rep"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s11894-019-0726-1","type":"journal-article","created":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T16:02:32Z","timestamp":1573660952000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Drug-Induced Small Bowel Injury: a Challenging and Often Forgotten Clinical Condition"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5645-857X","authenticated-orcid":false,"given":"Carmelo","family":"Scarpignato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingvar","family":"Bjarnason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,13]]},"reference":[{"key":"726_CR1","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/S0140-6736(00)02885-3","volume":"356","author":"RS Gruchalla","year":"2000","unstructured":"Gruchalla RS. Clinical assessment of drug-induced disease. Lancet. 2000;356:1505\u201311.","journal-title":"Lancet."},{"key":"726_CR2","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","volume":"356","author":"IR Edwards","year":"2000","unstructured":"Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356:1255\u20139.","journal-title":"Lancet."},{"key":"726_CR3","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2147\/CIA.S10252","volume":"6","author":"S Permpongkosol","year":"2011","unstructured":"Permpongkosol S. Iatrogenic disease in the elderly: risk factors, consequences, and prevention. Clin Interv Aging. 2011;6:77\u201382.","journal-title":"Clin Interv Aging."},{"key":"726_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1201\/9781315382579","volume-title":"Drug delivery: fundamentals and applications","author":"AM Hillery","year":"2016","unstructured":"Hillery AM, Park E. Drug delivery: fundamentals and applications. 2nd ed. Boca Raton: CRC Press; 2016. p. 1\u2013614.","edition":"2"},{"key":"726_CR5","first-page":"1","volume-title":"Stockley\u2019s drug interactions (12th Edition)","author":"CL Preston","year":"2019","unstructured":"Preston CL. Stockley\u2019s drug interactions (12th Edition). London: Pharmaceutical Press; 2019. p. 1\u20132048."},{"key":"726_CR6","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.pharmthera.2006.05.007","volume":"112","author":"M Treinen-Moslen","year":"2006","unstructured":"Treinen-Moslen M, Kanz MF. Intestinal tract injury by drugs: importance of metabolite delivery by yellow bile road. Pharmacol Ther. 2006;112:649\u201367.","journal-title":"Pharmacol Ther."},{"key":"726_CR7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/MCG.0b013e31818f9227","volume":"43","author":"V Jain","year":"2009","unstructured":"Jain V, Pitchumoni CS. Gastrointestinal side effects of prescription medications in the older adult. J Clin Gastroenterol. 2009;43:103\u201310.","journal-title":"J Clin Gastroenterol."},{"key":"726_CR8","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1136\/bmj.1.6173.1263","volume":"1","author":"PL Zentler-Munro","year":"1979","unstructured":"Zentler-Munro PL, Northfield TC. Drug-induced gastrointestinal disease. Br Med J. 1979;1:1263\u20135.","journal-title":"Br Med J."},{"key":"726_CR9","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/ncpgasthep0896","volume":"4","author":"MP Pusztaszeri","year":"2007","unstructured":"Pusztaszeri MP, Genta RM, Cryer BL. Drug-induced injury in the gastrointestinal tract: clinical and pathologic considerations. Nat Clin Pract Gastroenterol Hepatol. 2007;4:442\u201353.","journal-title":"Nat Clin Pract Gastroenterol Hepatol."},{"key":"726_CR10","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.mpdhp.2017.03.002","volume":"23","author":"AR Shih","year":"2017","unstructured":"Shih AR, Misdraji J. Drug-induced pathology of the upper gastrointestinal tract. Diagnostic Histopathology. 2017;23:84\u201395.","journal-title":"Diagnostic Histopathology."},{"key":"726_CR11","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.humpath.2007.01.014","volume":"38","author":"JR Parfitt","year":"2007","unstructured":"Parfitt JR, Driman DK. Pathological effects of drugs on the gastrointestinal tract: a review. Hum Pathol. 2007;38:527\u201336.","journal-title":"Hum Pathol."},{"key":"726_CR12","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1136\/postgradmedj-2013-100316rep","volume":"90","author":"HL Philpott","year":"2014","unstructured":"Philpott HL, Nandurkar S, Lubel J, et al. Drug-induced gastrointestinal disorders. Postgrad Med J. 2014;90:411\u20139.","journal-title":"Postgrad Med J."},{"key":"726_CR13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.bpg.2010.02.005","volume":"24","author":"R Tutuian","year":"2010","unstructured":"Tutuian R. Adverse effects of drugs on the esophagus. Best Pract Res Clin Gastroenterol. 2010;24:91\u20137.","journal-title":"Best Pract Res Clin Gastroenterol."},{"key":"726_CR14","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1159\/000357855","volume":"32","author":"Y Niv","year":"2014","unstructured":"Niv Y, Banic M. Gastric barrier function and toxic damage. Dig Dis. 2014;32:235\u201342.","journal-title":"Dig Dis."},{"key":"726_CR15","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000370205","volume":"33","author":"EV Marietta","year":"2015","unstructured":"Marietta EV, Cartee A, Rishi A, et al. Drug-induced enteropathy. Dig Dis. 2015;33:215\u201320.","journal-title":"Dig Dis."},{"key":"726_CR16","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.bpg.2010.02.008","volume":"24","author":"Z Zeino","year":"2010","unstructured":"Zeino Z, Sisson G, Bjarnason I. Adverse effects of drugs on small intestine and colon. Best Pract Res Clin Gastroenterol. 2010;24:133\u201341.","journal-title":"Best Pract Res Clin Gastroenterol."},{"key":"726_CR17","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1053\/j.gastro.2017.10.049","volume":"154","author":"I Bjarnason","year":"2018","unstructured":"\u2022\u2022 Bjarnason I, Scarpignato C, Holmgren E, et al. Mechanisms of damage to the gastrointestinal tract from nonsteroidal anti-inflammatory drugs. Gastroenterology. 2018;154:500\u201314 Comprehensive and up-to-date review on the meachanisms of NSAID GI damage.","journal-title":"Gastroenterology"},{"issue":"Suppl 3","key":"726_CR18","first-page":"S12","volume":"21","author":"R Guerciolini","year":"1997","unstructured":"Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord. 1997;21(Suppl 3):S12\u201323.","journal-title":"Int J Obes Relat Metab Disord."},{"key":"726_CR19","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2165\/00002018-200831010-00005","volume":"31","author":"TD Filippatos","year":"2008","unstructured":"Filippatos TD, Derdemezis CS, Gazi IF, et al. Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf. 2008;31:53\u201365.","journal-title":"Drug Saf."},{"key":"726_CR20","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1159\/000419988","volume":"20","author":"C Scarpignato","year":"1992","unstructured":"Scarpignato C. Cholecystokinin antagonists and motilides: pharmacology and potential in the treatment of gastroesophageal reflux disease and other digestive motor disorders. Front Gastrointest Res. 1992;20:90\u2013128.","journal-title":"Front Gastrointest Res."},{"key":"726_CR21","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2165\/00002018-199920010-00004","volume":"20","author":"N Principi","year":"1999","unstructured":"Principi N, Esposito S. Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric patients. Drug Saf. 1999;20:25\u201341.","journal-title":"Drug Saf."},{"key":"726_CR22","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1128\/AAC.35.6.1085","volume":"35","author":"F Caron","year":"1991","unstructured":"Caron F, Ducrotte P, Lerebours E, et al. Effects of amoxicillin-clavulanate combination on the motility of the small intestine in human beings. Antimicrob Agents Chemother. 1991;35:1085\u20138.","journal-title":"Antimicrob Agents Chemother."},{"key":"726_CR23","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1517\/14740330802527984","volume":"8","author":"F Salvo","year":"2009","unstructured":"Salvo F, De Sarro A, Caputi AP, et al. Amoxicillin and amoxicillin plus clavulanate: a safety review. Expert Opin Drug Saf. 2009;8:111\u20138.","journal-title":"Expert Opin Drug Saf."},{"key":"726_CR24","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1172\/JCI78366","volume":"124","author":"MJ Blaser","year":"2014","unstructured":"\u2022\u2022 Blaser MJ. The microbiome revolution. J Clin Invest. 2014;124:4162\u20135 Thoughtful paper summarizing the clinical relevance of the current knowledge on microbiome.","journal-title":"J Clin Invest"},{"key":"726_CR25","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nature25979","volume":"555","author":"L Maier","year":"2018","unstructured":"\u2022 Maier L, Pruteanu M, Kuhn M, et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018;555:623\u20138 Detailed paper evaluating the effect on non-antimicrobial drugs on human microbiota as well as the potential risks of promoting antibiotic resistance.","journal-title":"Nature"},{"key":"726_CR26","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/03602532.2018.1497647","volume":"50","author":"J Zhang","year":"2018","unstructured":"\u2022 Zhang J, Zhang J, Wang R. Gut microbiota modulates drug pharmacokinetics. Drug Metab Rev. 2018;50:357\u201368 Extensive review on the effects of gut microbiota on drug pharmacokinetics and its consequences on therapeutic effects and adverse effects of drugs.","journal-title":"Drug Metab Rev"},{"key":"726_CR27","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1111\/j.1572-0241.2005.00230.x","volume":"100","author":"G Barbara","year":"2005","unstructured":"Barbara G, Stanghellini V, Brandi G, et al. Interactions between commensal bacteria and gut sensorimotor function in health and disease. Am J Gastroenterol. 2005;100:2560\u20138.","journal-title":"Am J Gastroenterol."},{"issue":"Suppl 1","key":"726_CR28","doi-asserted-by":"crossref","first-page":"i6","DOI":"10.1093\/jac\/dky530","volume":"74","author":"AA Bhalodi","year":"2019","unstructured":"Bhalodi AA, van Engelen TSR, Virk HS, et al. Impact of antimicrobial therapy on the gut microbiome. J Antimicrob Chemother. 2019;74(Suppl 1):i6\u2013i15.","journal-title":"J Antimicrob Chemother."},{"key":"726_CR29","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12916-016-0718-z","volume":"14","author":"C Scarpignato","year":"2016","unstructured":"Scarpignato C, Gatta L, Zullo A, et al. Effective and safe proton pump inhibitor therapy in acid-related diseases - a position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14:179.","journal-title":"BMC Med"},{"key":"726_CR30","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/19490976.2017.1284732","volume":"8","author":"F Imhann","year":"2017","unstructured":"\u2022 Imhann F, Vich Vila A, Bonder MJ, et al. The influence of proton pump inhibitors and other commonly used medication on the gut microbiota. Gut Microbes. 2017;8:351\u20138 Summary of the PPI effects on gut microbiota.","journal-title":"Gut Microbes"},{"key":"726_CR31","unstructured":"Scarpignato C, Bertel\u00e9 A. The effect of proton pump inhibitors on gut microbiota. BiotaScope. 2016;2:7-18."},{"key":"726_CR32","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1017\/ice.2016.194","volume":"37","author":"V Arriola","year":"2016","unstructured":"Arriola V, Tischendorf J, Musuuza J, et al. Assessing the risk of hospital-acquired Clostridium difficile infection with proton pump inhibitor use: a meta-analysis. Infect Control Hosp Epidemiol. 2016;37:1408\u201317.","journal-title":"Infect Control Hosp Epidemiol."},{"key":"726_CR33","doi-asserted-by":"crossref","first-page":"e50836","DOI":"10.1371\/journal.pone.0050836","volume":"7","author":"IM Tleyjeh","year":"2012","unstructured":"Tleyjeh IM, Bin Abdulhak AA, Riaz M, et al. Association between proton pump inhibitor therapy and Clostridium difficile infection: a contemporary systematic review and meta-analysis. PLoS One. 2012;7:e50836.","journal-title":"PLoS One."},{"key":"726_CR34","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jhin.2017.08.017","volume":"98","author":"F Cao","year":"2018","unstructured":"Cao F, Chen CX, Wang M, et al. Updated meta-analysis of controlled observational studies: proton-pump inhibitors and risk of Clostridium difficile infection. J Hosp Infect. 2018;98:4\u201313.","journal-title":"J Hosp Infect."},{"key":"726_CR35","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1017\/ice.2014.88","volume":"36","author":"A Deshpande","year":"2015","unstructured":"Deshpande A, Pasupuleti V, Thota P, et al. Risk factors for recurrent Clostridium difficile infection: a systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2015;36:452\u201360.","journal-title":"Infect Control Hosp Epidemiol."},{"key":"726_CR36","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1001\/jamainternmed.2017.0212","volume":"177","author":"R Tariq","year":"2017","unstructured":"Tariq R, Singh S, Gupta A, et al. Association of gastric acid suppression with recurrent Clostridium difficile infection: a systematic review and meta-analysis. JAMA Intern Med. 2017;177:784\u201391.","journal-title":"JAMA Intern Med."},{"key":"726_CR37","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00535-017-1371-9","volume":"53","author":"T Su","year":"2018","unstructured":"Su T, Lai S, L\u2019ee A, et al. Meta-analysis: proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth. J Gastroenterol. 2018;53:27\u201336.","journal-title":"J Gastroenterol."},{"issue":"5","key":"726_CR38","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.cgh.2012.12.011","volume":"11","author":"Wai\u2013Kit Lo","year":"2013","unstructured":"Lo W-K, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11.","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"726_CR39","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3109\/00365521.2014.880182","volume":"49","author":"M Muraki","year":"2014","unstructured":"Muraki M, Fujiwara Y, Machida H, et al. Role of small intestinal bacterial overgrowth in severe small intestinal damage in chronic non-steroidal anti-inflammatory drug users. Scand J Gastroenterol. 2014;49:267\u201373.","journal-title":"Scand J Gastroenterol."},{"key":"726_CR40","doi-asserted-by":"crossref","first-page":"809-15.e1","DOI":"10.1016\/j.cgh.2015.10.022","volume":"14","author":"E Washio","year":"2016","unstructured":"\u2022 Washio E, Esaki M, Maehata Y, et al. Proton pump inhibitors increase incidence of nonsteroidal anti-inflammatory drug-induced small bowel injury: a randomized, placebo-controlled trial. Clin Gastroenterol Hepatol. 2016;14:809-15.e1 Seminal paper, showing that PPIs almost nullify the improved intestinal tolerability of the selective COX-2 inhibitor, celecoxib.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"726_CR41","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s12185-017-2373-3","volume":"107","author":"D Girelli","year":"2018","unstructured":"Girelli D, Ugolini S, Busti F, et al. Modern iron replacement therapy: clinical and pathophysiological insights. Int J Hematol. 2018;107:16\u201330.","journal-title":"Int J Hematol."},{"key":"726_CR42","doi-asserted-by":"crossref","first-page":"e0117383","DOI":"10.1371\/journal.pone.0117383","volume":"10","author":"Z Tolkien","year":"2015","unstructured":"Tolkien Z, Stecher L, Mander AP, et al. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PLoS One. 2015;10:e0117383.","journal-title":"PLoS One."},{"key":"726_CR43","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.trstmh.2005.10.016","volume":"100","author":"M Nchito","year":"2006","unstructured":"Nchito M, Friis H, Michaelsen KF, et al. Iron supplementation increases small intestine permeability in primary schoolchildren in Lusaka, Zambia. Trans R Soc Trop Med Hyg. 2006;100:791\u20134.","journal-title":"Trans R Soc Trop Med Hyg."},{"key":"726_CR44","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/BF03259863","volume":"2","author":"EC Tozman","year":"1987","unstructured":"Tozman EC, Gottlieb NL. Adverse reactions with oral and parenteral gold preparations. Med Toxicol. 1987;2:177\u201389.","journal-title":"Med Toxicol."},{"key":"726_CR45","first-page":"222","volume":"10","author":"PL van Riel","year":"1983","unstructured":"van Riel PL, Gribnau FW, van de Putte LB, et al. Loose stools during auranofin treatment: clinical study and some pathogenetic possibilities. J Rheumatol. 1983;10:222\u20136.","journal-title":"J Rheumatol."},{"key":"726_CR46","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1136\/gut.27.1.59","volume":"27","author":"R Behrens","year":"1986","unstructured":"Behrens R, Devereaux M, Hazleman B, et al. Investigation of auranofin-induced diarrhoea. Gut. 1986;27:59\u201365.","journal-title":"Gut."},{"key":"726_CR47","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/rheumatology\/34.4.395","volume":"34","author":"NJ Cook","year":"1995","unstructured":"Cook NJ, Owen ET, Donlon JB. A further possible cause of diarrhoea caused by oral gold. Br J Rheumatol. 1995;34:395\u20136.","journal-title":"Br J Rheumatol."},{"key":"726_CR48","first-page":"769","volume":"78","author":"J Backon","year":"1983","unstructured":"Backon J. Gold-induced diarrhea and the role of prostaglandins. Am J Gastroenterol. 1983;78:769.","journal-title":"Am J Gastroenterol."},{"key":"726_CR49","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2165\/00002512-199813030-00007","volume":"13","author":"RN Ratnaike","year":"1998","unstructured":"Ratnaike RN, Jones TE. Mechanisms of drug-induced diarrhoea in the elderly. Drugs Aging. 1998;13:245\u201353.","journal-title":"Drugs Aging."},{"key":"726_CR50","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3389\/fphar.2016.00414","volume":"7","author":"RM McQuade","year":"2016","unstructured":"\u2022 McQuade RM, Stojanovska V, Abalo R, et al. Chemotherapy-induced constipation and diarrhea: pathophysiology, current and emerging treatments. Front Pharmacol. 2016;7:414 Recent review on chemotherapy-induced constipation and diarrhea.","journal-title":"Front Pharmacol"},{"key":"726_CR51","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2165\/00002018-200022010-00005","volume":"22","author":"O Chassany","year":"2000","unstructured":"Chassany O, Michaux A, Bergmann JF. Drug-induced diarrhoea. Drug Saf. 2000;22:53\u201372.","journal-title":"Drug Saf."},{"key":"726_CR52","doi-asserted-by":"crossref","first-page":"17095","DOI":"10.1038\/nrdp.2017.95","volume":"3","author":"M Camilleri","year":"2017","unstructured":"\u2022\u2022 Camilleri M, Ford AC, Mawe GM, et al. Chronic constipation. Nat Rev Dis Primers. 2017;3:17095 State-of-the-art review on chronic constipation.","journal-title":"Nat Rev Dis Primers"},{"key":"726_CR53","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1472-6904-11-2","volume":"11","author":"GS Fosnes","year":"2011","unstructured":"Fosnes GS, Lydersen S, Farup PG. Constipation and diarrhoea - common adverse drug reactions? A cross sectional study in the general population. BMC Clin Pharmacol. 2011;11:2.","journal-title":"BMC Clin Pharmacol"},{"key":"726_CR54","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.disamonth.2011.05.006","volume":"57","author":"P Deepak","year":"2011","unstructured":"Deepak P, Ehrenpreis ED. Constipation. Dis Mon. 2011;57:511\u20137.","journal-title":"Dis Mon."},{"key":"726_CR55","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.humpath.2015.12.001","volume":"50","author":"N Burbure","year":"2016","unstructured":"\u2022 Burbure N, Lebwohl B, Arguelles-Grande C, et al. Olmesartan-associated sprue-like enteropathy: a systematic review with emphasis on histopathology. Hum Pathol. 2016;50:127\u201334 Comprehensive review on olmesartan-induced celiac-like enteropathy.","journal-title":"Hum Pathol"},{"key":"726_CR56","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/pds.4402","volume":"27","author":"P Malfertheiner","year":"2018","unstructured":"Malfertheiner P, Ripellino C, Cataldo N. Severe intestinal malabsorption associated with ACE inhibitor or angiotensin receptor blocker treatment. An observational cohort study in Germany and Italy. Pharmacoepidemiol Drug Saf. 2018;27:581\u20136.","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"726_CR57","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/j.1399-0012.2008.00892.x","volume":"22","author":"S Bunnapradist","year":"2008","unstructured":"Bunnapradist S, Ambuhl PM. Impact of gastrointestinal-related side effects on mycophenolate mofetil dosing and potential therapeutic strategies. Clin Transplant. 2008;22:815\u201321.","journal-title":"Clin Transplant."},{"key":"726_CR58","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1600-6143.2010.03423.x","volume":"11","author":"H Weclawiak","year":"2011","unstructured":"Weclawiak H, Ould-Mohamed A, Bournet B, et al. Duodenal villous atrophy: a cause of chronic diarrhea after solid-organ transplantation. Am J Transplant. 2011;11:575\u201382.","journal-title":"Am J Transplant."},{"key":"726_CR59","doi-asserted-by":"crossref","first-page":"101","DOI":"10.14309\/crj.2016.13","volume":"3","author":"A Jehangir","year":"2016","unstructured":"Jehangir A, Shaikh B, Hunt J, et al. Severe enteropathy from mycophenolate mofetil. ACG Case Rep J. 2016;3:101\u20133.","journal-title":"ACG Case Rep J."},{"key":"726_CR60","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.2146\/ajhp140085","volume":"71","author":"BF Curtin","year":"2014","unstructured":"Curtin BF, Rachakonda VP, Von Rosenvinge EC. Unusually late-onset mycophenolate mofetil-related colitis. Am J Health Syst Pharm. 2014;71:1858\u201361.","journal-title":"Am J Health Syst Pharm."},{"key":"726_CR61","first-page":"3058407","volume":"2016","author":"A Goyal","year":"2016","unstructured":"Goyal A, Salahuddin M, Govil Y. A unique case of mycophenolate induced colitis after 10 years of use. Case Rep Gastrointest Med. 2016;2016:3058407.","journal-title":"Case Rep Gastrointest Med."},{"key":"726_CR62","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/ctr.12452","volume":"28","author":"LG de Andrade","year":"2014","unstructured":"de Andrade LG, Rodrigues MA, Romeiro FG, et al. Clinicopathologic features and outcome of mycophenolate-induced colitis in renal transplant recipients. Clin Transplant. 2014;28:1244\u20138.","journal-title":"Clin Transplant."},{"key":"726_CR63","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/jclinpath-2012-200888","volume":"66","author":"S Lee","year":"2013","unstructured":"Lee S, de Boer WB, Subramaniam K, et al. Pointers and pitfalls of mycophenolate-associated colitis. J Clin Pathol. 2013;66:8\u201311.","journal-title":"J Clin Pathol."},{"key":"726_CR64","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/his.12222","volume":"63","author":"G Liapis","year":"2013","unstructured":"Liapis G, Boletis J, Skalioti C, et al. Histological spectrum of mycophenolate mofetil-related colitis: association with apoptosis. Histopathology. 2013;63:649\u201358.","journal-title":"Histopathology."},{"key":"726_CR65","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1093\/ndt\/gfm308","volume":"22","author":"NM Davies","year":"2007","unstructured":"Davies NM, Grinyo J, Heading R, et al. Gastrointestinal side effects of mycophenolic acid in renal transplant patients: a reappraisal. Nephrol Dial Transplant. 2007;22:2440\u20138.","journal-title":"Nephrol Dial Transplant."},{"key":"726_CR66","doi-asserted-by":"crossref","first-page":"685","DOI":"10.12659\/AOT.889299","volume":"18","author":"A Kaltenborn","year":"2013","unstructured":"Kaltenborn A, Schrem H. Mycophenolate mofetil in liver transplantation: a review. Ann Transplant. 2013;18:685\u201396.","journal-title":"Ann Transplant."},{"key":"726_CR67","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1016\/j.transproceed.2010.08.066","volume":"42","author":"AI Al-Absi","year":"2010","unstructured":"Al-Absi AI, Cooke CR, Wall BM, et al. Patterns of injury in mycophenolate mofetil-related colitis. Transplant Proc. 2010;42:3591\u20133.","journal-title":"Transplant Proc."},{"key":"726_CR68","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/CCO.0b013e3281214412","volume":"19","author":"DM Keefe","year":"2007","unstructured":"Keefe DM. Intestinal mucositis: mechanisms and management. Curr Opin Oncol. 2007;19:323\u20137.","journal-title":"Curr Opin Oncol."},{"key":"726_CR69","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00280-016-3139-y","volume":"78","author":"RA Ribeiro","year":"2016","unstructured":"Ribeiro RA, Wanderley CW, Wong DV, et al. Irinotecan- and 5-fluorouracil-induced intestinal mucositis: insights into pathogenesis and therapeutic perspectives. Cancer Chemother Pharmacol. 2016;78:881\u201393.","journal-title":"Cancer Chemother Pharmacol."},{"key":"726_CR70","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/apt.12878","volume":"40","author":"Y Touchefeu","year":"2014","unstructured":"Touchefeu Y, Montassier E, Nieman K, et al. Systematic review: the role of the gut microbiota in chemotherapy- or radiation-induced gastrointestinal mucositis - current evidence and potential clinical applications. Aliment Pharmacol Ther. 2014;40:409\u201321.","journal-title":"Aliment Pharmacol Ther."},{"key":"726_CR71","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.3892\/mco.2015.635","volume":"3","author":"SF Lee","year":"2015","unstructured":"Lee SF, Chiang CL, Lee AS, et al. Severe ileitis associated with capecitabine: two case reports and review of the literature. Mol Clin Oncol. 2015;3:1398\u2013400.","journal-title":"Mol Clin Oncol."},{"key":"726_CR72","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1159\/000492781","volume":"11","author":"IEG van Hellemond","year":"2018","unstructured":"van Hellemond IEG, Thijs AM, Creemers GJ. Capecitabine-associated terminal ileitis. Case Rep Oncol. 2018;11:654\u20139.","journal-title":"Case Rep Oncol."},{"key":"726_CR73","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nrgastro.2018.14","volume":"15","author":"MA Samaan","year":"2018","unstructured":"\u2022\u2022 Samaan MA, Pavlidis P, Papa S, et al. Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management. Nat Rev Gastroenterol Hepatol. 2018;15:222\u201334 Comprehensive review on the clinical use and GI toxicity of immune checkpoint inhibitors.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"726_CR74","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1136\/gutjnl-2018-316948","volume":"67","author":"E Soularue","year":"2018","unstructured":"\u2022\u2022 Soularue E, Lepage P, Colombel JF, et al. Enterocolitis due to immune checkpoint inhibitors: a systematic review. Gut. 2018;67:2056\u201367 Complete review on the pathogenesis, clinical picture, and diagnosis of enterocolitis associated to immune checkpoint inhibitor therapy.","journal-title":"Gut"},{"key":"726_CR75","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/CJI.0b013e318193a206","volume":"32","author":"S Bhatia","year":"2009","unstructured":"Bhatia S, Huber BR, Upton MP, et al. Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report. J Immunother. 2009;32:203\u20135.","journal-title":"J Immunother."},{"key":"726_CR76","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/CJI.0b013e31827807dd","volume":"36","author":"C Gaudy-Marqueste","year":"2013","unstructured":"Gaudy-Marqueste C, Monestier S, Franques J, et al. A severe case of ipilimumab-induced Guillain-Barre syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis. J Immunother. 2013;36:77\u20138.","journal-title":"J Immunother."},{"key":"726_CR77","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJM199808133390707","volume":"339","author":"FJ Gennari","year":"1998","unstructured":"Gennari FJ. Hypokalemia. N Engl J Med. 1998;339:451\u20138.","journal-title":"N Engl J Med."},{"key":"726_CR78","first-page":"1001","volume":"193","author":"AC Allen","year":"1965","unstructured":"Allen AC, Boley SJ, Schultz L, et al. Potassium-induced lesions of the small bowel. II. Pathology and pathogenesis. Jama. 1965;193:1001\u20136.","journal-title":"II. Pathology and pathogenesis. Jama."},{"key":"726_CR79","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1159\/000197141","volume":"4","author":"D Birnbaum","year":"1971","unstructured":"Birnbaum D, Levy M. Diuretics and adverse gastrointestinal reaction. Digestion. 1971;4:362\u20136.","journal-title":"Digestion."},{"key":"726_CR80","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1001\/jama.1965.03080080031007","volume":"191","author":"FD Lawrason","year":"1965","unstructured":"Lawrason FD, Alpert E, Mohr FL, et al. Ulcerative-obstructive lesions of the small intestine. J A M A. 1965;191:641\u20134.","journal-title":"J A M A."},{"key":"726_CR81","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1136\/bmj.2.5973.746","volume":"2","author":"SJ Heffernan","year":"1975","unstructured":"Heffernan SJ, Murphy JJ. Letter: Ulceration of small intestine and slow-release potassium tablets. Br Med J. 1975;2:746.","journal-title":"Br Med J."},{"key":"726_CR82","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.gtc.2010.08.010","volume":"39","author":"C Scarpignato","year":"2010","unstructured":"Scarpignato C, Hunt RH. Nonsteroidal antiinflammatory drug-related injury to the gastrointestinal tract: clinical picture, pathogenesis, and prevention. Gastroenterol Clin North Am. 2010;39:433\u201364.","journal-title":"Gastroenterol Clin North Am."},{"key":"726_CR83","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7326\/0003-4819-123-4-199508150-00001","volume":"123","author":"FE Silverstein","year":"1995","unstructured":"Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995;123:241\u20139.","journal-title":"Ann Intern Med."},{"key":"726_CR84","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1053\/gast.2003.50054","volume":"124","author":"L Laine","year":"2003","unstructured":"Laine L, Connors LG, Reicin A, et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology. 2003;124:288\u201392.","journal-title":"Gastroenterology."},{"key":"726_CR85","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/ajg.2009.164","volume":"104","author":"A Lanas","year":"2009","unstructured":"Lanas A, Garcia-Rodriguez LA, Polo-Tomas M, et al. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol. 2009;104:1633\u201341.","journal-title":"Am J Gastroenterol."},{"key":"726_CR86","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.dld.2015.01.005","volume":"47","author":"L Xiong","year":"2015","unstructured":"Xiong L, Huang X, Li L, et al. Geranylgeranylacetone protects against small-intestinal injuries induced by diclofenac in patients with rheumatic diseases: a prospective randomized study. Dig Liver Dis. 2015;47:280\u20134.","journal-title":"Dig Liver Dis."},{"key":"726_CR87","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1159\/000443361","volume":"34","author":"FR Ponziani","year":"2016","unstructured":"Ponziani FR, Scaldaferri F, Petito V, et al. The role of antibiotics in gut microbiota modulation: the eubiotic effects of rifaximin. Dig Dis. 2016;34:269\u201378.","journal-title":"Dig Dis."},{"key":"726_CR88","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00535-013-0805-2","volume":"49","author":"S Kurokawa","year":"2014","unstructured":"Kurokawa S, Katsuki S, Fujita T, et al. A randomized, double-blinded, placebo-controlled, multicenter trial, healing effect of rebamipide in patients with low-dose aspirin and\/or non-steroidal anti-inflammatory drug induced small bowel injury. J Gastroenterol. 2014;49:239\u201344.","journal-title":"J Gastroenterol."},{"key":"726_CR89","doi-asserted-by":"crossref","first-page":"e0122330","DOI":"10.1371\/journal.pone.0122330","volume":"10","author":"T Watanabe","year":"2015","unstructured":"Watanabe T, Takeuchi T, Handa O, et al. A multicenter, randomized, double-blind, placebo-controlled trial of high-dose rebamipide treatment for low-dose aspirin-induced moderate-to-severe small intestinal damage. PLoS One. 2015;10:e0122330.","journal-title":"PLoS One."},{"key":"726_CR90","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1471-230X-13-85","volume":"13","author":"T Kuramoto","year":"2013","unstructured":"Kuramoto T, Umegaki E, Nouda S, et al. Preventive effect of irsogladine or omeprazole on non-steroidal anti-inflammatory drug-induced esophagitis, peptic ulcers, and small intestinal lesions in humans, a prospective randomized controlled study. BMC Gastroenterol. 2013;13:85.","journal-title":"BMC Gastroenterol."},{"key":"726_CR91","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1136\/gut.45.3.362","volume":"45","author":"JA Tibble","year":"1999","unstructured":"Tibble JA, Sigthorsson G, Foster R, et al. High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut. 1999;45:362\u20136.","journal-title":"Gut."},{"key":"726_CR92","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00535-012-0648-2","volume":"48","author":"M Montalto","year":"2013","unstructured":"Montalto M, Gallo A, Gasbarrini A, et al. NSAID enteropathy: could probiotics prevent it? J Gastroenterol. 2013;48:689\u201397.","journal-title":"J Gastroenterol."},{"key":"726_CR93","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12916-015-0285-8","volume":"13","author":"C Scarpignato","year":"2015","unstructured":"Scarpignato C, Lanas A, Blandizzi C, et al. Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis--an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. BMC Med. 2015;13:55.","journal-title":"BMC Med."},{"key":"726_CR94","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00535-009-0102-2","volume":"44","author":"K Higuchi","year":"2009","unstructured":"Higuchi K, Umegaki E, Watanabe T, et al. Present status and strategy of NSAIDs-induced small bowel injury. J Gastroenterol. 2009;44:879\u201388.","journal-title":"J Gastroenterol."},{"key":"726_CR95","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1159\/000374106","volume":"91","author":"K Takeuchi","year":"2015","unstructured":"Takeuchi K, Satoh H. NSAID-induced small intestinal damage--roles of various pathogenic factors. Digestion. 2015;91:218\u201332.","journal-title":"Digestion."},{"key":"726_CR96","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.gie.2008.08.017","volume":"69","author":"S Fujimori","year":"2009","unstructured":"Fujimori S, Seo T, Gudis K, et al. Prevention of nonsteroidal anti-inflammatory drug-induced small-intestinal injury by prostaglandin: a pilot randomized controlled trial evaluated by capsule endoscopy. Gastrointest Endosc. 2009;69:1339\u201346.","journal-title":"Gastrointest Endosc."},{"key":"726_CR97","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s00535-007-2155-4","volume":"43","author":"Y Niwa","year":"2008","unstructured":"Niwa Y, Nakamura M, Ohmiya N, et al. Efficacy of rebamipide for diclofenac-induced small-intestinal mucosal injuries in healthy subjects: a prospective, randomized, double-blinded, placebo-controlled, cross-over study. J Gastroenterol. 2008;43:270\u20136.","journal-title":"J Gastroenterol."},{"key":"726_CR98","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00535-010-0332-3","volume":"46","author":"S Fujimori","year":"2011","unstructured":"Fujimori S, Takahashi Y, Gudis K, et al. Rebamipide has the potential to reduce the intensity of NSAID-induced small intestinal injury: a double-blind, randomized, controlled trial evaluated by capsule endoscopy. J Gastroenterol. 2011;46:57\u201364.","journal-title":"J Gastroenterol."},{"key":"726_CR99","doi-asserted-by":"crossref","first-page":"5117","DOI":"10.3748\/wjg.v17.i46.5117","volume":"17","author":"K Mizukami","year":"2011","unstructured":"Mizukami K, Murakami K, Abe T, et al. Aspirin-induced small bowel injuries and the preventive effect of rebamipide. World J Gastroenterol. 2011;17:5117\u201322.","journal-title":"World J Gastroenterol."},{"issue":"Suppl 1","key":"726_CR100","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000089789","volume":"73","author":"A Lanas","year":"2006","unstructured":"Lanas A, Scarpignato C. Microbial flora in NSAID-induced intestinal damage: a role for antibiotics? Digestion. 2006;73(Suppl 1):136\u201350.","journal-title":"Digestion."},{"key":"726_CR101","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3389\/fimmu.2017.00036","volume":"8","author":"C Pellegrini","year":"2017","unstructured":"Pellegrini C, Antonioli L, Lopez-Castejon G, et al. Canonical and non-canonical activation of NLRP3 inflammasome at the crossroad between immune tolerance and intestinal inflammation. Front Immunol. 2017;8:36.","journal-title":"Front Immunol."},{"key":"726_CR102","doi-asserted-by":"crossref","first-page":"679","DOI":"10.2165\/00003495-199754050-00003","volume":"54","author":"CD Freeman","year":"1997","unstructured":"Freeman CD, Klutman NE, Lamp KC. Metronidazole. A therapeutic review and update. Drugs. 1997;54:679\u2013708.","journal-title":"Drugs."},{"key":"726_CR103","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0140-6736(84)92739-9","volume":"2","author":"I Bjarnason","year":"1984","unstructured":"Bjarnason I, Williams P, So A, et al. Intestinal permeability and inflammation in rheumatoid arthritis: effects of non-steroidal anti-inflammatory drugs. Lancet. 1984;2:1171\u20134.","journal-title":"Lancet."},{"key":"726_CR104","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0140-6736(87)91075-0","volume":"2","author":"I Bjarnason","year":"1987","unstructured":"Bjarnason I, Zanelli G, Prouse P, et al. Blood and protein loss via small-intestinal inflammation induced by non-steroidal anti-inflammatory drugs. Lancet. 1987;2:711\u20134.","journal-title":"Lancet."},{"key":"726_CR105","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1542-3565(04)00603-2","volume":"3","author":"DY Graham","year":"2005","unstructured":"Graham DY, Opekun AR, Willingham FF, et al. Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol. 2005;3:55\u20139.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"726_CR106","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1053\/j.gastro.2005.03.020","volume":"128","author":"L Maiden","year":"2005","unstructured":"Maiden L, Thjodleifsson B, Theodors A, et al. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology. 2005;128:1172\u20138.","journal-title":"Gastroenterology."},{"key":"726_CR107","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.3390\/ph3041187","volume":"3","author":"S Fujimori","year":"2010","unstructured":"Fujimori S, Gudis K, Sakamoto C. A review of anti-inflammatory drug-induced gastrointestinal injury: focus on prevention of small intestinal injury. Pharmaceuticals. 2010;3:1187\u2013201.","journal-title":"Pharmaceuticals."},{"key":"726_CR108","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/j.1365-2036.2006.03043.x","volume":"24","author":"L Laine","year":"2006","unstructured":"Laine L, Smith R, Min K, et al. Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2006;24:751\u201367.","journal-title":"Aliment Pharmacol Ther."},{"key":"726_CR109","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S1542-3565(04)00619-6","volume":"3","author":"JL Goldstein","year":"2005","unstructured":"Goldstein JL, Eisen GM, Lewis B, et al. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol. 2005;3:133\u201341.","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"10","key":"726_CR110","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1111\/j.1365-2036.2007.03312.x","volume":"25","author":"J. L. GOLDSTEIN","year":"2007","unstructured":"Goldstein JL, Eisen GM, Lewis B, et al. Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy. Aliment Pharmacol Ther. 2007;25:1211\u201322.","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"726_CR111","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.coph.2014.05.008","volume":"19","author":"RW Blackler","year":"2014","unstructured":"Blackler RW, Gemici B, Manko A, et al. NSAID-gastroenteropathy: new aspects of pathogenesis and prevention. Curr Opin Pharmacol. 2014;19:11\u20136.","journal-title":"Curr Opin Pharmacol."},{"key":"726_CR112","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1136\/gut.2007.134502","volume":"57","author":"C Scarpignato","year":"2008","unstructured":"Scarpignato C. NSAID-induced intestinal damage: are luminal bacteria the therapeutic target? Gut. 2008;57:145\u20138.","journal-title":"Gut."},{"key":"726_CR113","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.clinbiochem.2007.01.015","volume":"40","author":"M Petruzzelli","year":"2007","unstructured":"Petruzzelli M, Vacca M, Moschetta A, et al. Intestinal mucosal damage caused by non-steroidal anti-inflammatory drugs: role of bile salts. Clin Biochem. 2007;40:503\u201310.","journal-title":"Clin Biochem."},{"key":"726_CR114","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.cca.2009.12.026","volume":"411","author":"K Takeuchi","year":"2010","unstructured":"Takeuchi K, Tanaka A, Kato S, et al. Roles of COX inhibition in pathogenesis of NSAID-induced small intestinal damage. Clin Chim Acta. 2010;411:459\u201366.","journal-title":"Clin Chim Acta."},{"key":"726_CR115","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/mi.2015.89","volume":"9","author":"A Higashimori","year":"2016","unstructured":"Higashimori A, Watanabe T, Nadatani Y, et al. Mechanisms of NLRP3 inflammasome activation and its role in NSAID-induced enteropathy. Mucosal Immunol. 2016;9:659\u201368.","journal-title":"Mucosal Immunol."},{"key":"726_CR116","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1136\/gut.33.9.1204","volume":"33","author":"I Bjarnason","year":"1992","unstructured":"Bjarnason I, Hayllar J, Smethurst P, et al. Metronidazole reduces intestinal inflammation and blood loss in non-steroidal anti-inflammatory drug induced enteropathy. Gut. 1992;33:1204\u20138.","journal-title":"Gut."},{"key":"726_CR117","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.phrs.2015.12.031","volume":"104","author":"M Fornai","year":"2015","unstructured":"Fornai M, Antonioli L, Pellegrini C, et al. Small bowel protection against NSAID-injury in rats: effect of rifaximin, a poorly absorbed, GI targeted, antibiotic. Pharmacol Res. 2015;104:186\u201396.","journal-title":"Pharmacol Res."},{"key":"726_CR118","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.3389\/fphar.2018.01340","volume":"9","author":"R Colucci","year":"2018","unstructured":"\u2022 Colucci R, Pellegrini C, Fornai M, et al. Pathophysiology of NSAID-associated intestinal lesions in the rat: luminal bacteria and mucosal inflammation as targets for prevention. Front Pharmacol. 2018;9:1340 Experimental paper detailing the mechanisms underlying the enteroprotective effects of rifaximin.","journal-title":"Front Pharmacol"},{"key":"726_CR119","doi-asserted-by":"crossref","first-page":"980-82 e3","DOI":"10.1053\/j.gastro.2016.12.007","volume":"152","author":"C Scarpignato","year":"2017","unstructured":"\u2022\u2022 Scarpignato C, Dolak W, Lanas A, et al. Rifaximin reduces the number and severity of intestinal lesions associated with use of nonsteroidal anti-inflammatory drugs in humans. Gastroenterology. 2017;152:980-82 e3 First demonstration of the involvement of enteric bacteria in the pathogenesis of NSAID enteropathy in humans.","journal-title":"Gastroenterology"},{"key":"726_CR120","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.gie.2013.12.030","volume":"80","author":"Y Isomura","year":"2014","unstructured":"Isomura Y, Yamaji Y, Yamada A, et al. Irsogladine improves small-intestinal injuries in regular users of nonsteroidal anti-inflammatory drugs. Gastrointest Endosc. 2014;80:118\u201325.","journal-title":"Gastrointest Endosc."},{"key":"726_CR121","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2169\/internalmedicine.53.1572","volume":"53","author":"E Umegaki","year":"2014","unstructured":"Umegaki E, Kuramoto T, Kojima Y, et al. Geranylgeranylacetone, a gastromucoprotective drug, protects against NSAID-induced esophageal, gastroduodenal and small intestinal mucosal injury in healthy subjects: a prospective randomized study involving a comparison with famotidine. Intern Med. 2014;53:283\u201390.","journal-title":"Intern Med."},{"key":"726_CR122","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.cgh.2008.06.021","volume":"6","author":"T Watanabe","year":"2008","unstructured":"Watanabe T, Sugimori S, Kameda N, et al. Small bowel injury by low-dose enteric-coated aspirin and treatment with misoprostol: a pilot study. Clin Gastroenterol Hepatol. 2008;6:1279\u201382.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"726_CR123","first-page":"1090-97.e1","volume":"155","author":"MH Kyaw","year":"2018","unstructured":"Kyaw MH, Otani K, Ching JYL, et al. Misoprostol heals small bowel ulcers in aspirin users with small bowel bleeding. Gastroenterology. 2018;155:1090-97.e1.","journal-title":"Gastroenterology"},{"key":"726_CR124","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S2468-1253(18)30119-5","volume":"3","author":"AS Taha","year":"2018","unstructured":"Taha AS, McCloskey C, McSkimming P, et al. Misoprostol for small bowel ulcers in patients with obscure bleeding taking aspirin and non-steroidal anti-inflammatory drugs (MASTERS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2018;3:469\u201376.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"726_CR125","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJM199211263272207","volume":"327","author":"RP Walt","year":"1992","unstructured":"Walt RP. Misoprostol for the treatment of peptic ulcer and antiinflammatory-drug-induced gastroduodenal ulceration. N Engl J Med. 1992;327:1575\u201380.","journal-title":"N Engl J Med."},{"key":"726_CR126","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1023\/A:1018895417831","volume":"43","author":"FE Silverstein","year":"1998","unstructured":"Silverstein FE. Improving the gastrointestinal safety of NSAIDs: the development of misoprostol--from hypothesis to clinical practice. Dig Dis Sci. 1998;43:447\u201358.","journal-title":"Dig Dis Sci."},{"key":"726_CR127","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000357229","volume":"89","author":"T Inoue","year":"2014","unstructured":"Inoue T, Iijima H, Arimitsu J, et al. Amelioration of small bowel injury by switching from nonselective nonsteroidal anti-inflammatory drugs to celecoxib in rheumatoid arthritis patients: a pilot study. Digestion. 2014;89:124\u201332.","journal-title":"Digestion."},{"key":"726_CR128","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/00000478-200001000-00016","volume":"24","author":"S Sukpanichnant","year":"2000","unstructured":"Sukpanichnant S, Hargrove NS, Kachintorn U, et al. Clofazimine-induced crystal-storing histiocytosis producing chronic abdominal pain in a leprosy patient. Am J Surg Pathol. 2000;24:129\u201335.","journal-title":"Am J Surg Pathol."},{"key":"726_CR129","doi-asserted-by":"crossref","first-page":"197","DOI":"10.4103\/0253-7613.108323","volume":"45","author":"H Singh","year":"2013","unstructured":"Singh H, Azad K, Kaur K. Clofazimine-induced enteropathy in a patient of leprosy. Indian J Pharmacol. 2013;45:197\u20138.","journal-title":"Indian J Pharmacol."},{"key":"726_CR130","first-page":"281","volume":"47","author":"MV Jadhav","year":"2004","unstructured":"Jadhav MV, Sathe AG, Deore SS, et al. Tissue concentration, systemic distribution and toxicity of clofazimine--an autopsy study. Indian J Pathol Microbiol. 2004;47:281\u20133.","journal-title":"Indian J Pathol Microbiol."},{"key":"726_CR131","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1742-1241.1998.tb08900.x","volume":"52","author":"A Hameed","year":"1998","unstructured":"Hameed A, Beach FX, Kennedy RH, et al. A case of clofazimine enteropathy. Int J Clin Pract. 1998;52:439\u201340.","journal-title":"Int J Clin Pract."},{"key":"726_CR132","first-page":"364","volume":"57","author":"DK Bhasin","year":"1985","unstructured":"Bhasin DK, Kumar B, Broor SL, et al. Effect of clofazimine: detailed studies of small intestine functions. Indian J Lepr. 1985;57:364\u201372.","journal-title":"Indian J Lepr."},{"key":"726_CR133","doi-asserted-by":"crossref","first-page":"234","DOI":"10.7326\/0003-4819-117-3-234","volume":"117","author":"ZH Israili","year":"1992","unstructured":"Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med. 1992;117:234\u201342.","journal-title":"Ann Intern Med."},{"key":"726_CR134","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3949\/ccjm.78a.10102","volume":"78","author":"A Korniyenko","year":"2011","unstructured":"Korniyenko A, Alviar CL, Cordova JP, et al. Visceral angioedema due to angiotensin-converting enzyme inhibitor therapy. Cleve Clin J Med. 2011;78:297\u2013304.","journal-title":"Cleve Clin J Med."},{"key":"726_CR135","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/bjs.1800640802","volume":"64","author":"M Hoyle","year":"1977","unstructured":"Hoyle M, Kennedy A, Prior AL, et al. Small bowel ischaemia and infarction in young women taking oral contraceptives and progestational agents. Br J Surg. 1977;64:533\u20137.","journal-title":"Br J Surg."},{"key":"726_CR136","first-page":"350","volume":"145","author":"DJ Schneiderman","year":"1986","unstructured":"Schneiderman DJ, Cello JP. Intestinal ischemia and infarction associated with oral contraceptives. West J Med. 1986;145:350\u20135.","journal-title":"West J Med."},{"key":"726_CR137","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1097\/MEG.0000000000000915","volume":"29","author":"R Ortizo","year":"2017","unstructured":"Ortizo R, Lee SY, Nguyen ET, et al. Exposure to oral contraceptives increases the risk for development of inflammatory bowel disease: a meta-analysis of case-controlled and cohort studies. Eur J Gastroenterol Hepatol. 2017;29:1064\u201370.","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"726_CR138","doi-asserted-by":"crossref","first-page":"392","DOI":"10.4318\/tjg.2013.0697","volume":"24","author":"F Altintoprak","year":"2013","unstructured":"Altintoprak F, Dikicier E, Akyuz M, et al. A retrospective review of patients with non-traumatic spontaneous intramural hematoma. Turk J Gastroenterol. 2013;24:392\u20139.","journal-title":"Turk J Gastroenterol."},{"key":"726_CR139","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1590\/S1807-59322007000600020","volume":"62","author":"MP Sorbello","year":"2007","unstructured":"Sorbello MP, Utiyama EM, Parreira JG, et al. Spontaneous intramural small bowel hematoma induced by anticoagulant therapy: review and case report. Clinics (Sao Paulo). 2007;62:785\u201390.","journal-title":"Clinics (Sao Paulo)"},{"key":"726_CR140","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.2214\/ajr.179.6.1791389","volume":"179","author":"MA Abbas","year":"2002","unstructured":"Abbas MA, Collins J, Olden K. Spontaneous intramural small-bowel hematoma: imaging findings and outcome. Am J Roentgenol. 2002;179:1389\u201398.","journal-title":"Am J Roentgenol."},{"key":"726_CR141","first-page":"8780121","volume":"2018","author":"BH Choi","year":"2018","unstructured":"Choi BH, Koeckert M, Tomita S. Intramural bowel hematoma presenting as small bowel obstruction in a patient on low-molecular-weight heparin. Case Rep Pediatr. 2018;2018:8780121.","journal-title":"Case Rep Pediatr."},{"key":"726_CR142","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1093\/qjmed\/hcs105","volume":"105","author":"R Flower","year":"2012","unstructured":"Flower R. The Osler Lecture 2012: \u2018pharmacology 2.0, medicines, drugs and human enhancement\u2019. QJM. 2012;105:823\u201330.","journal-title":"QJM."}],"container-title":["Current Gastroenterology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-019-0726-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11894-019-0726-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-019-0726-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T21:32:10Z","timestamp":1722029530000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11894-019-0726-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":142,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["726"],"URL":"https:\/\/doi.org\/10.1007\/s11894-019-0726-1","relation":{},"ISSN":["1522-8037","1534-312X"],"issn-type":[{"value":"1522-8037","type":"print"},{"value":"1534-312X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"13 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Ingvar Bjarnason declares no conflict of interest.Carmelo Scarpignato has served as a speaker, consultant, and\/or advisory board member for Alfasigma, Pfizer, Takeda, Reckitt Benckiser, and Shionogi and has in the past received funding from Giuliani Pharmaceuticals and Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"55"}}